Search

STUDY OBJECTIVES: Recently, criteria have been drawn up for large muscle group movements during sleep (LMM), defined as movements lasting for 3-45 seconds in adults, which are often accompanied by changes in sleep stage, arousals, and increases in heart rate. The aim of this study was to characterize LMM in restless legs syndrome (RLS) in order to better evaluate their impact on the neurophysiology of the disorder and, therefore, the possible clinical implications. METHODS: Consecutive, drug-free patients diagnosed with RLS and controls, aged 18 years or more, were retrospectively enrolled. Leg movement activity-short-interval (SILMS), periodic (PLMS), and isolated (ISOLMS) leg movements during sleep-and LMM were detected and scored. RESULTS: In total, 100 patients and 67 controls were recruited. All movement measures were significantly higher in RLS. A significant positive correlation was found between LMM and ISOLMS index but not PLMS index in both groups. LMM index showed a significant negative correlation with total sleep time, sleep efficiency, and percentage of sleep stages N3 and R, as well as a significant positive correlation with the number of awakenings, and percentage of sleep stages N1 and N2 only in patients with RLS. No significant correlation was found between either LMM or PLMS index and RLS severity. CONCLUSIONS: Different types of movements, including SILMS, ISOLMS, and LMM, play somewhat distinct roles in sleep neurophysiology in RLS. Notably, LMM, a newly recognized category of movements, demonstrates associations with sleep architecture instability and fragmentation, arousals, and awakenings, suggesting potential clinical implications.

Background: Calcitonin gene-related peptide monoclonal antibody (CGRP mAb) effects on restless legs syndrome (RLS) are unclear. Methods: Fifteen migraine patients (aged 49.1 ± 5.8 years; 14 women) with concomitant RLS who received CGRP mAbs (2 erenumab, 3 galcanezumab, and 10 fremanezumab) were retrospectively studied. Number of monthly migraine days (MMDs) was obtained from headache diaries. The primary outcome is changes in RLS severity as assessed by the International RLS Group Rating Scale (IRLS). Headache-related disability was assessed using the Migraine Disability Assessment (MIDAS). The severity of headache and RLS was rated using the Patient Global Impression of Change (PGIC) scale. Central sensitization was evaluated with the Central Sensitization Inventory (CSI). Results: At 1, 2, and 3 months, the percentages of patients with ≥ 50% improvement in number of MMDs were 53.3%, 66.6%, and 60.0%, respectively. From baseline to 3 months, there were significant reductions in the MIDAS (25.1 ± 23.2 vs. 19.7 ± 22.8, p = 0.005) and CSI scores (36.3 ± 12.9 vs. 29.1 ± 12.3, p = 0.001). IRLS scores decreased significantly from baseline to 1 month (-8.8 ± 2.1 points) and 3 months (-11.6 ± 2.3 points) after CGRP mAb treatment. On the PGIC scale, 86.7% and 73.3% of patients reported at least "minimal improvement" in migraine and RLS severity, respectively, with 46.7% and 26.7% reporting "very much improvement". Among those with a < 50% reduction in number of MMDs at 3 months, 66.6% reported at least "minimal improvement", with 33.3% reporting "very much improvement". Conclusion: Our study revealed that 3-month CGRP mAb treatment significantly alleviated RLS symptoms, central sensitization and headache-related disability in patients with comorbid migraine and RLS. [ABSTRACT FROM AUTHOR]

To evaluate factors associated with sleep related injury (SRI) and persistent SRI (pSRI) in patients with isolated rapid eye movement sleep behavior disorder (iRBD). This is a retrospective cohort study. A total of 388 patients with iRBD were involved for a comprehensive review of sleep related injuries. SRI is defined as a lifetime history of injurious behaviors to self and/or bed partner, and pSRI is considered if injurious symptoms continued to occur frequently (≥1/month). Correlations of SRI/pSRI with clinical, lifestyle and polysomnographic characteristics were analyzed. Lifetime SRI was reported in 322 (83 %) patients (66.3 ± 8.5 years old, male 77.0 %), with 19.3 % having severe injuries, including fractures (2.5 %) and subdural hemorrhage (1.2 %), while 7.5 % required medical attendance. SRI was related to more severe depressive features (P adj = 0.017), current alcohol drinking (P adj = 0.014) and higher mentalis phasic and tonic EMG activity (P adj = 0.042 and 0.048). After a mean follow-up of 5.1 years, 18.2 % of SRI patients (38/209) had pSRI despite intense treatment. Frequent nightmare at baseline (OR [95 % CI] = 1.43 [1.01, 2.03]), restless leg syndrome (OR [95 % CI] = 5.68 [1.42, 22.64]) and adult-onset sleepwalking (OR [95 % CI] = 2.52 [1.10, 5.76]) were associated with an increased risk of pSRI. SRI is common in patients with iRBD and 18 % had pSRI despite intensive treatment, emphasizing the importance of bedside safety. The identification of risk factors for SRI and pSRI underscores the need for systematic clinical screening and targeted interventions for at-risk patients. SRI: Sleep-related injury; RBD, rapid eye movement sleep behavior disorder. [Display omitted] • Sleep-related injury (SRI) is a major clinical concern occurring in 83 % REM sleep behavior disorder (RBD) patients. • Risk factors for SRI includes male sex, depressive feature, alcohol use and higher mentalis EMG activity. • Despite treatment, 18 % RBD patients have persistent SRI linked to nightmare, sleepwalking and restless leg syndrome. • Comprehensive screening and targeted management of risk factors are crucial in RBD care. [ABSTRACT FROM AUTHOR]

Introduction: In Parkinson's disease (PD), sleep–wake problems are disease-related symptoms that occur throughout the day and have a negative impact on patients' quality of life to an extent that is equal to or greater than that of typical motor symptoms. Areas covered: Insomnia due to fragmented sleep and excessive daytime sleepiness (EDS) worsen as PD progresses. Nighttime wearing-off and early morning-off should be considered first when fragmented sleep is reported in PD patients. If the main complaint of patients with insomnia is difficulty falling asleep, restless legs syndrome should be differentiated first. Obstructive sleep apnea causes sleep quality deterioration and fragmented sleep. For rapid eye movement sleep behavior disorder (RBD), preventative measures against sleep-related trauma are necessary. RBD has also attracted attention as a PD precursor state and as a disease progression marker that is associated with specific PD clinical subtypes. In PD patients, the sleep–wake phase may advance/delay or become irregular due to circadian dysfunction. Expert opinion: Importantly, sleep–wake problems are core symptoms related to the pathogenesis and progression of PD, and addressing a wide range of these symptoms will improve patients' quality of life. [ABSTRACT FROM AUTHOR]

Copyright of Clinical Neuroscience / Ideggyógyászati Szemle is the property of LifeTime Media Kft. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Introduction: Restless legs syndrome (RLS) is a sensorimotor disorder of the nervous system that is mainly characterized by nighttime leg discomfort and can be accompanied by significant anxiety, depression, and other mood disorders. RLS seriously affects the quality of life. Clinical studies have confirmed that acupuncture can alleviate the clinical symptoms of RLS. This randomized controlled trial (RCT) aims to investigate the efficacy of acupuncture in the treatment of RLS and further explore the central response mechanism of acupuncture in the treatment of RLS. Methods and analysis: In this RCT, a total of 124 eligible patients in Shanghai will be randomly assigned to one of the following two groups: treatment group (acupuncture) and control group (sham acupuncture). Treatment will be given three times per week for 4 consecutive weeks. The primary outcome is the International Restless Legs severity rating scale (IRLSS). The secondary outcomes are the RLS-Quality of Life (RLSQoL), the Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index (PSQI), the Hamilton Depression Scale (HAMD), and the Hamilton Anxiety Scale (HAMA). The objective evaluation tools will be polysomnography, positron emission tomography–computed tomography (PET-CT), and functional magnetic resonance imaging (fMRI) of the brain. All adverse effects will be assessed by the Treatment Emergent Symptom Scale. Outcomes will be evaluated at baseline (1 week before the first intervention), during the intervention (the second week of the intervention), after the intervention (at the end of the intervention), at 1-month follow-up, and at 3-month follow-up. Ethics and dissemination: The trial has been approved by the Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine (no. 2022-061). Written informed consent will be obtained from all participants. The results of this study will be published in peer-reviewed journals or presented at academic conferences. Clinical trial registration: https://www.chictr.org.cn/ , identifier ChiCTR2000037287. [ABSTRACT FROM AUTHOR]

We aimed to investigate the frequency of restless legs syndrome (RLS) and neuropathic pain (NeP) in patients with Takayasu arteritis (TAK), and their relationship with disease activity, and quality of life (QoL). In this prospective case-control study, we evaluated 30 patients with TAK and 28 healthy subjects. Demographic, clinical, and current treatment-related data were also recorded. RLS diagnosis was confirmed in both groups according to the International Restless Legs Study Group criteria. The Douleur neuropathic-4 questionnaire (DN4) confirmed the frequency of neuropathic pain, and the quality of life was confirmed by the Short Form 36 (SF-36) health survey questionnaire. Univariate logistic regression analyses were performed to estimate the odds ratio (OR) for factors associated with NeP in patients with TAK. There was no statistically significant difference in the diagnosis of RLS between the TAK group and the control group (p = 0.195). The prevalence of NeP was significantly higher in TAK patients than in healthy controls (p = 0.011). The SF-36 subscale scores for physical functioning (p = 0.01) and general health (p = 0.002) were significantly lower in the TAK group than in the control group. Vasculitis Damage Index (VDI) scores were considerably higher in patients with NeP (p = 0.004). In univariate analyses, VDI decreased unbound iron-binding capacity, and SF36 mental component summary were predictors associated with NeP. This study revealed that the frequency of NeP was higher in patients with TAK than in the healthy population, and the patients with TAK were negatively affected in terms of NeP and QoL rather than RLS. [ABSTRACT FROM AUTHOR]

Background: Restless legs syndrome (RLS) with insomnia is presumed to be associated with antenatal depression. RLS without insomnia, however, has not been investigated in association with antenatal depression. We aimed to examine whether RLS without insomnia during pregnancy is associated with antenatal depressive symptoms. Methods: This cross-sectional study used data from a randomized controlled trial (RCT) assessing antenatal depressive symptoms among Japanese pregnant women. The participants were 2,108 women who attended the RCT at 16–20 weeks of pregnancy. RLS, insomnia, and antenatal depressive symptoms were assessed using the Cambridge-Hopkins questionnaire short form, Insomnia Severity Index, and Edinburgh Postnatal Depression Scale, respectively. Associations of antenatal depressive symptoms with RLS and insomnia were examined using logistic regression analysis, adjusting for age, partner, education, children, and planned pregnancy. Results: Of the total participants, 206 (9.8%) had antenatal depressive symptoms; 80 (3.8%) had RLS. The mean age (standard deviation) was 30.4 (4.6) years. RLS was positively associated with antenatal depressive symptoms: the odds ratio was 2.30 (95% confidence interval, 1.28–4.16). RLS without insomnia was positively associated with antenatal depressive symptoms, as well as insomnia without RLS and RLS with insomnia: the odds ratio was 2.44 (95% confidence interval, 1.09–5.46) for RLS without insomnia, 3.83 (2.78–5.28) for insomnia without RLS, and 5.80 (2.42–13.92) for RLS with insomnia, compared to neither RLS nor insomnia. Conclusions: We observed the positive association between RLS without insomnia and antenatal depressive symptoms, suggesting the importance of assessing and treating RLS without insomnia during pregnancy for the reduction of antenatal depressive symptoms. [ABSTRACT FROM AUTHOR]